543 related articles for article (PubMed ID: 21262918)
21. The probiotic VSL#3 has anti-inflammatory effects and could reduce endoscopic recurrence after surgery for Crohn's disease.
Fedorak RN; Feagan BG; Hotte N; Leddin D; Dieleman LA; Petrunia DM; Enns R; Bitton A; Chiba N; Paré P; Rostom A; Marshall J; Depew W; Bernstein CN; Panaccione R; Aumais G; Steinhart AH; Cockeram A; Bailey RJ; Gionchetti P; Wong C; Madsen K
Clin Gastroenterol Hepatol; 2015 May; 13(5):928-35.e2. PubMed ID: 25460016
[TBL] [Abstract][Full Text] [Related]
22. Steroid-sparing properties of sargramostim in patients with corticosteroid-dependent Crohn's disease: a randomised, double-blind, placebo-controlled, phase 2 study.
Valentine JF; Fedorak RN; Feagan B; Fredlund P; Schmitt R; Ni P; Humphries TJ
Gut; 2009 Oct; 58(10):1354-62. PubMed ID: 19505878
[TBL] [Abstract][Full Text] [Related]
23. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial.
Sandborn WJ; Hanauer SB; Rutgeerts P; Fedorak RN; Lukas M; MacIntosh DG; Panaccione R; Wolf D; Kent JD; Bittle B; Li J; Pollack PF
Gut; 2007 Sep; 56(9):1232-9. PubMed ID: 17299059
[TBL] [Abstract][Full Text] [Related]
24. A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease.
Schreiber S; Rutgeerts P; Fedorak RN; Khaliq-Kareemi M; Kamm MA; Boivin M; Bernstein CN; Staun M; Thomsen OØ; Innes A;
Gastroenterology; 2005 Sep; 129(3):807-18. PubMed ID: 16143120
[TBL] [Abstract][Full Text] [Related]
25. Randomised clinical trial: vercirnon, an oral CCR9 antagonist, vs. placebo as induction therapy in active Crohn's disease.
Feagan BG; Sandborn WJ; D'Haens G; Lee SD; Allez M; Fedorak RN; Seidler U; Vermeire S; Lawrance IC; Maroney AC; Jurgensen CH; Heath A; Chang DJ
Aliment Pharmacol Ther; 2015 Nov; 42(10):1170-81. PubMed ID: 26400458
[TBL] [Abstract][Full Text] [Related]
26. Analysis of the intestinal microbiota of oligosaccharide fed mice exhibiting reduced resistance to Salmonella infection.
Petersen A; Bergström A; Andersen JB; Hansen M; Lahtinen SJ; Wilcks A; Licht TR
Benef Microbes; 2010 Sep; 1(3):271-81. PubMed ID: 21831764
[TBL] [Abstract][Full Text] [Related]
27. A randomised placebo-controlled multicentre trial of intravenous semapimod HCl for moderate to severe Crohn's disease.
Dotan I; Rachmilewitz D; Schreiber S; Eliakim R; van der Woude CJ; Kornbluth A; Buchman AL; Bar-Meir S; Bokemeyer B; Goldin E; Maaser C; Mahadevan U; Seidler U; Hoffman JC; Homoky D; Plasse T; Powers B; Rutgeerts P; Hommes D;
Gut; 2010 Jun; 59(6):760-6. PubMed ID: 20551461
[TBL] [Abstract][Full Text] [Related]
28. Natalizumab for active Crohn's disease.
Ghosh S; Goldin E; Gordon FH; Malchow HA; Rask-Madsen J; Rutgeerts P; Vyhnálek P; Zádorová Z; Palmer T; Donoghue S;
N Engl J Med; 2003 Jan; 348(1):24-32. PubMed ID: 12510039
[TBL] [Abstract][Full Text] [Related]
29. A preliminary study of growth hormone therapy for Crohn's disease.
Slonim AE; Bulone L; Damore MB; Goldberg T; Wingertzahn MA; McKinley MJ
N Engl J Med; 2000 Jun; 342(22):1633-7. PubMed ID: 10833209
[TBL] [Abstract][Full Text] [Related]
30. Fontolizumab, a humanised anti-interferon gamma antibody, demonstrates safety and clinical activity in patients with moderate to severe Crohn's disease.
Hommes DW; Mikhajlova TL; Stoinov S; Stimac D; Vucelic B; Lonovics J; Zákuciová M; D'Haens G; Van Assche G; Ba S; Lee S; Pearce T
Gut; 2006 Aug; 55(8):1131-7. PubMed ID: 16507585
[TBL] [Abstract][Full Text] [Related]
31. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.
Targan SR; Hanauer SB; van Deventer SJ; Mayer L; Present DH; Braakman T; DeWoody KL; Schaible TF; Rutgeerts PJ
N Engl J Med; 1997 Oct; 337(15):1029-35. PubMed ID: 9321530
[TBL] [Abstract][Full Text] [Related]
32. Intravenous CDP870, a PEGylated Fab' fragment of a humanized antitumour necrosis factor antibody, in patients with moderate-to-severe Crohn's disease: an exploratory study.
Winter TA; Wright J; Ghosh S; Jahnsen J; Innes A; Round P
Aliment Pharmacol Ther; 2004 Dec; 20(11-12):1337-46. PubMed ID: 15606396
[TBL] [Abstract][Full Text] [Related]
33. A randomized, double-blind, placebo-controlled trial of lenalidomide in the treatment of moderately severe active Crohn's disease.
Mansfield JC; Parkes M; Hawthorne AB; Forbes A; Probert CS; Perowne RC; Cooper A; Zeldis JB; Manning DC; Hawkey CJ
Aliment Pharmacol Ther; 2007 Aug; 26(3):421-30. PubMed ID: 17635377
[TBL] [Abstract][Full Text] [Related]
34. Low-dose cyclosporine for the treatment of Crohn's disease. The Canadian Crohn's Relapse Prevention Trial Investigators.
Feagan BG; McDonald JW; Rochon J; Laupacis A; Fedorak RN; Kinnear D; Saibil F; Groll A; Archambault A; Gillies R
N Engl J Med; 1994 Jun; 330(26):1846-51. PubMed ID: 8196727
[TBL] [Abstract][Full Text] [Related]
35. A mixture of prebiotic oligosaccharides reduces the incidence of atopic dermatitis during the first six months of age.
Moro G; Arslanoglu S; Stahl B; Jelinek J; Wahn U; Boehm G
Arch Dis Child; 2006 Oct; 91(10):814-9. PubMed ID: 16873437
[TBL] [Abstract][Full Text] [Related]
36. A randomised crossover study investigating the effects of galacto-oligosaccharides on the faecal microbiota in men and women over 50 years of age.
Walton GE; van den Heuvel EG; Kosters MH; Rastall RA; Tuohy KM; Gibson GR
Br J Nutr; 2012 May; 107(10):1466-75. PubMed ID: 21910949
[TBL] [Abstract][Full Text] [Related]
37. A dose escalating, placebo controlled, double blind, single dose and multidose, safety and tolerability study of fontolizumab, a humanised anti-interferon gamma antibody, in patients with moderate to severe Crohn's disease.
Reinisch W; Hommes DW; Van Assche G; Colombel JF; Gendre JP; Oldenburg B; Teml A; Geboes K; Ding H; Zhang L; Tang M; Cheng M; van Deventer SJ; Rutgeerts P; Pearce T
Gut; 2006 Aug; 55(8):1138-44. PubMed ID: 16492717
[TBL] [Abstract][Full Text] [Related]
38. Validation of endoscopic activity scores in patients with Crohn's disease based on a post hoc analysis of data from SONIC.
Ferrante M; Colombel JF; Sandborn WJ; Reinisch W; Mantzaris GJ; Kornbluth A; Rachmilewitz D; Lichtiger S; D'Haens GR; van der Woude CJ; Danese S; Diamond RH; Oortwijn AF; Tang KL; Miller M; Cornillie F; Rutgeerts PJ;
Gastroenterology; 2013 Nov; 145(5):978-986.e5. PubMed ID: 23954314
[TBL] [Abstract][Full Text] [Related]
39. A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease.
Sandborn WJ; Feagan BG; Fedorak RN; Scherl E; Fleisher MR; Katz S; Johanns J; Blank M; Rutgeerts P;
Gastroenterology; 2008 Oct; 135(4):1130-41. PubMed ID: 18706417
[TBL] [Abstract][Full Text] [Related]
40. Faecal microbiota and short-chain fatty acids in patients receiving enteral nutrition with standard or fructo-oligosaccharides and fibre-enriched formulas.
Majid HA; Emery PW; Whelan K
J Hum Nutr Diet; 2011 Jun; 24(3):260-8. PubMed ID: 21414042
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
